The disclosure provide hollow nanospheres and methods of making and using the same. The methods and compositions of the disclosure are useful for drug delivery and gene transfer.

A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications.

The present application provides methods of treating a colon cancer (such as advanced and/or metastatic colon cancer) in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, b) an effective amount of anti-VEGF antibody (such as bevacizumab), and c) a therapeutically effective FOLFOX regimen (such as FOLFOX4 or a modified FOLFOX6).

A composition includes a plurality of stabilized crosslinked nanobubbles, each nanobubble having a membrane that defines at least one internal void, which includes at least one gas, the membrane including at least one lipid, at least one nonionic triblock copolymer that is effective to control the size of the nanobubble without compromising in vitro and in vivo echogenicity of the nanobubble, and an interpenetrating crosslinked biodegradable polymer.

Embodiments of the disclosure concern methods and compositions for treatment of a cardiac-related medical condition. In particular embodiments, ANGPTL8 is provided to an individual in need thereof for the treatment or prevention of a cardiac-related medical condition. In certain cases, ANGPTL8 is provided to an individual with cardiomyopathy, such as Adriamycin-induced cardiomyopathy, using ultrasound-targeted microbubble destruction.

The present disclosure relates to a method for treating mitochondrial complex I deficiency comprising administering to patients with mitochondrial complex I deficiency an effective amount of XBIR3. The effective amount of XBIR 3 may be conjugated to a cell-penetrating peptide, such conjugation may include encapsulation of XBIR3 in nano-carrier that is conjugated to a cell penetrating peptide or direct conjugation of XBIR3 to a cell penetrating peptide. The XBIR-3 conjugated to a cell-penetrating peptide may be administered directly to the eye of the patient, administered systemically, or administered intranasally.

The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

It could be helpful to provide albumin to which a water-soluble polymer that has high biocompatibility and is easily prepared (synthesized) is bound; and an artificial plasma expander and a hemorrhagic shock resuscitation fluid that each contain the water-soluble polymer-bound albumin. The solution is a polyoxazoline-bound albumin (100) including an albumin (10) as a core and a polyoxazoline (20) as a shell, which is covalently bound to the albumin (10) via a cross-linker; and an artificial plasma expander and a hemorrhagic shock resuscitation fluid that each contain the polyoxazoline-bound albumin (100).

The present invention relates to compositions and methods for effective delivery of an agent to a stem cell using a delivery vehicle comprising a stem cell targeting domain.

The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell.